Surgery and Oncology, Год журнала: 2025, Номер 15(1), С. 28 - 35
Опубликована: Март 20, 2025
Background . Pancreatic cancer (PC) has long been a disease with limited treatment options, where the foundation of therapy was primarily based on cytostatics. However, advent first KRAS G12C inhibitors, new prospects have emerged for advanced PC, highlighting importance studying mutations, which occur in 80–95 % cases. In this context, it is relevant to analyze frequency various mutations among Russian population patients could help personalize further diagnostics and therapy. Aim. To study features status younger older than 65 years pancreatic adenocarcinoma real clinical practice. Materials methods. We retrospectively analyzed data 590 who underwent molecular genetic research at N. Blokhin from 2022 2024. Patients primary multiple malignancies were excluded study. Inclusion criteria presence histological verification diagnosis known KRAS, NRAS, BRCA 1/2, CHEK2, PALB2, ATM status. divided into two age groups, years. The endpoint comparative assessment mutation rate both groups. Results. 129 included analysis. detection wild-type general 24.8 %. most common groups p.G12V p.G12D , accounting 79.2 all gene. p.G12C detected (2 %). Five clinically significant 1/2 genes identified; patient mBRCA1 had wild type remaining 4 BRCA2 also mutation. Conclusion. Given increasing number drugs that affect ability detect other alterations wtKRAS integration testing routine practice evaluation necessary.
Язык: Английский
